-
Ocrelizumab provides superior control of multiple sclerosis relapses compared to other therapies
24 Sep 2025 01:58 GMT
… European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2025) … of multiple sclerosis (MS) relapses compared with fingolimod, natalizumab, and alemtuzumab.
Ocrelizumab … the urgent need for treatments that target relapse-independent …
-
New multi-registry study highlights ocrelizumab’s superior relapse control in multiple sclerosis
23 Sep 2025 22:25 GMT
… of multiple sclerosis (MS) relapses compared with fingolimod, natalizumab, and alemtuzumab.1 … .
Compared with natalizumab and alemtuzumab, ocrelizumab also showed lower … , where she focuses on multiple sclerosis treatment effectiveness. She has served on …
-
<![CDATA[Phase 2a INFORM-MS Trial to Study Anti-CD3 Agent Foralumab in Nonactive Secondary Progressive MS]]>
25 Sep 2025 16:52 GMT
… progressive multiple sclerosis, a population with limited treatment options.… -risk agents like alemtuzumab or mitoxantrone. Other … of neurology at Harvard Medical School, added, … trial of nasal foralumab in non-active secondary progressive multiple sclerosis …
-
Gaps in Observational Data Challenge Understanding of Infection Risk in MS Treatments
23 Aug 2025 19:43 GMT
… multiple sclerosis (MS) who receive disease-modifying treatments (DMTs).1 Although clinical trials … randomized trial data.
The Multiple Sclerosis … Amsterdam University Medical Center … , natalizumab, ocrelizumab, alemtuzumab, cladribine, and teriflunomide …
-
Global Multiple Sclerosis Treatment Market To Reach $31.55 Billion By 2029 With A Growth Rate Of 4.8%.
01 Jul 2025 10:56 GMT
… -based pharmaceutical company introduced Ocrevus Ocrelizumab for treating multiple sclerosis MS. This drug that …
3 By Symptomatic Treatments: Muscle Relaxants, Antidepressants, Anticonvulsants, Bladder Dysfunction Drugs
4 By …
-
Multiple Sclerosis Clinical Trial Pipeline Shows Potential with Active Contributions from 60+ Key Companies | DelveInsight
24 Jun 2025 17:00 GMT
… Pharmaceutical, GlaxoSmithKline, ImCyse, and others are evaluating new multiple sclerosis medications to improve the treatment … the new multiple sclerosis drug @ Multiple Sclerosis Clinical Trials Key Developments in the Multiple Sclerosis Treatment Space
…
-
Multiple Sclerosis Clinical Trial Pipeline Shows Potential With Active Contributions From 60+ Key Companies Delveinsight
24 Jun 2025 17:19 GMT
… Pharmaceutical, GlaxoSmithKline, ImCyse, and others are evaluating new multiple sclerosis medications to improve the treatment … the new multiple sclerosis drug @ Multiple Sclerosis Clinical Trials Key Developments in the Multiple Sclerosis Treatment Space In …
-
Christina Applegate hospitalized: Inside her double kidney infection amid MS struggles (symptoms, risk factors, treatment)
06 Aug 2025 05:25 GMT
… to her left. Doctors initially suspected a … the disease yet, treatment for multiple sclerosis (MS) focuses … natalizumab, ocrelizumab, and alemtuzumab. Treating relapses:
Corticosteroids: … Pain management: Various medications like amitriptyline, pregabalin, …
-
Multiple Sclerosis Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight
05 Jun 2025 02:05 GMT
… Pharmaceuticals, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Stem Cell Medicine … Multiple Sclerosis Clinical Trials Assessment
Multiple sclerosis Emerging Drugs Profile … trial for the treatment of multiple sclerosis. …
-
Personalizing Care: Treatment Decisions in Sézary Syndrome
11 Jul 2025 14:23 GMT
… often used as first-line treatment due to potential for durable … by HDAC inhibitors, photopheresis, or Alemtuzumab depending on disease progression and …
About
© 1995-2025